How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Clinical Trial Recruitment and Real World Evidence (RWE) Market
- By Service Type: Patient Recruitment Services, Site Management Services, Data Management and Analytics, Real World Evidence Generation, Regulatory Consulting
- By End User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Academic and Research Institutions, Healthcare Providers, Regulatory Authorities
- By Data Source for RWE: Electronic Health Records (EHR), Claims and Billing Data, Patient Registries, Wearable Devices and Mobile Health Apps, Genomic Data
- By Therapeutic Area: Oncology, Cardiovascular Diseases, Neurology, Infectious Diseases, Rare Diseases
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Patient Recruitment Services leads By Service Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Clinical Trial Recruitment and Real World Evidence (RWE) Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Service Type 5
End User 5
Data Source for RWE 5
Therapeutic Area 5
Companies profiled
IQVIA
PPD (Pharmaceutical Product Development)
Parexel International
ICON plc
Syneos Health
Covance (Labcorp Drug Development)
Medidata Solutions (Dassault Systèmes)
Charles River Laboratories
PRA Health Sciences (now part of ICON plc)
Verily Life Sciences
TrialSpark
Science 37
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →IQVIA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →PPD (Pharmaceutical Product Development)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Parexel International
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →ICON plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Syneos Health
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Covance (Labcorp Drug Development)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Medidata Solutions (Dassault Systèmes)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Charles River Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →PRA Health Sciences (now part of ICON plc)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Verily Life Sciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →TrialSpark
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Science 37
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Deep 6 AI
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Antidote Technologies
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Curebase
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,842M by 2033 · 11.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Patient Recruitment Services49.5
- Site Management Services13.9
- Data Management and Analytics8.0
- Real World Evidence Generation16.6
- Regulatory Consulting11.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$663.1M → $1,682M · 12.3%
Europe$462.2M → $1,094M · 11.4%
Asia Pacific$422.0M → $1,002M · 11.4%
Latin America$261.2M → $702.5M · 13.2%
Middle East and Africa$201.0M → $433.1M · 10.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.582026
11.582027
11.612028
11.622029
11.632030
11.642031
11.652032
11.652033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- IQVIA26.5
- PPD (Pharmaceutical Product Development)15.2
- Parexel International8.8
- ICON plc5.6
- Syneos Health5.3
- Covance (Labcorp Drug Development)10.5
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Service Type30.4%
End User24.5%
Data Source for RWE12.0%
Therapeutic Area33.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.2
- Europe22.3
- Asia Pacific20.4
- Latin America14.3
- Middle East and Africa8.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| IQVIA | 97 | 95 | 83 | 79 | 90 | 85 | 88 |
| PPD (Pharmaceutical Product Development) | 72 | 68 | 89 | 85 | 70 | 72 | 76 |
| Parexel International | 74 | 79 | 76 | 66 | 75 | 76 | 74 |
| ICON plc | 76 | 57 | 59 | 81 | 75 | 57 | 68 |
| Syneos Health | 71 | 70 | 67 | 72 | 63 | 54 | 66 |
| Covance (Labcorp Drug Development) | 57 | 48 | 53 | 71 | 70 | 66 | 61 |
| Medidata Solutions (Dassault Systèmes) | 62 | 59 | 41 | 44 | 61 | 59 | 54 |
| Charles River Laboratories | 49 | 51 | 54 | 49 | 46 | 42 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- IQVIA
- PPD (Pharmaceutical Product Development)
- Parexel International
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| IQVIA | ✓ | ✓ | ✓ | ◐ | ◐ | ✓ |
| PPD (Pharmaceutical Product Development) | ◐ | − | ◐ | ◐ | ✓ | ✓ |
| Parexel International | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| ICON plc | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Syneos Health | ◐ | ✓ | ✓ | ✓ | − | − |
| Covance (Labcorp Drug Development) | ◐ | − | − | ◐ | ◐ | ◐ |
| Medidata Solutions (Dassault Systèmes) | − | − | − | ◐ | ◐ | − |
| Charles River Laboratories | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1IQVIA88
2PPD (Pharmaceutical Product Development)76
3Parexel International74
4ICON plc68
5Syneos Health66
6Covance (Labcorp Drug Development)61
7Medidata Solutions (Dassault Systèmes)54
8Charles River Laboratories49
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
IQVIA
Challenger3
Strong scale, closing on the leaders.
PPD (Pharmaceutical Product Development)Parexel InternationalICON plc
Contender2
Focused players with pockets of strength.
Syneos HealthCovance (Labcorp Drug Development)
Niche2
Specialists in a single segment or region.
Medidata Solutions (Dassault Systèmes)Charles River Laboratories
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Service Type in North America, then scale across Clinical Trial Recruitment and Real World Evidence (RWE) Market — a $185M beachhead inside a $3.19B market.
Beachhead (SOM)$185Mobtainable near-term
Serviceable (SAM)$1.30Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Patient Recruitment Services
Best fit — highest urgency & budget in Service Type.
Economic buyer80 fit
Site Management Services
Strong fit — clear ROI and a fast path to value.
End user68 fit
Data Management and Analytics
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Service Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Data Source for RWE
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel28%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Service Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Clinical Trial Recruitment and Real World Evidence (RWE) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified22%
Evaluation13%
Closed-won7%
$13.8KCAC
$71KLTV
5.1:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Clinical Trial Recruitment and Real World Evidence (RWE) Market is a high-growth opportunity — $4.29B by 2033, compounding at 10.5%.
TAM · 2025$1.93Btoday
TAM · 2033$4.29Bforecast
CAGR10.5%2027–2033
Cumulative$26.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.29BTotal addressable market
SAM$1.67BServiceable available market
SOM$292MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.5% CAGR
Demand compounds through 2033, outpacing GDP across Service Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Service Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.29BLarge & growingTAM by 2033 at 10.5% CAGR
$1.67BServiceable nowreachable with today’s model
$292MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.35BBear6.8% CAGR
$4.29BBase10.5% CAGR
$5.50BBull13.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Clinical Trial Recruitment and Real World Evidence (RWE) Market — a $7.38B market by 2033. Plan: grow share from 7.3% to 13.3%.
Market size · 2033$7.38Btotal addressable
Market CAGR11.0%2027–2033
Target share13.3%from 7.3% today
Revenue ambition$982Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.3% | 13.3% | At risk |
| Revenue | $584M | $982M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 31.9% | 44.2% | At risk |
| Customer retention | 86.8% | 96.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Service Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Service Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $113M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Service Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Clinical Trial Recruitment and Real World Evidence (RWE) Market conversation — a $11.0B market you can size, segment and defend in minutes.
Market size · 2033$11.0Btotal opportunity
Growth11.4%CAGR to 2033
Addressable buyers1,352+accounts in scope
Typical ROI6.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Service Type
Goal Grow share in Service Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.7×return on cost, year one
< 4 mopayback period
$94K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
IQVIAPPD (Pharmaceutical Product Development)Parexel InternationalICON plcSyneos HealthCovance (Labcorp Drug Development)Medidata Solutions (Dassault Systèmes)Charles River Laboratories+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Clinical Trial Recruitment and Real World Evidence (RWE) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Clinical Trial Recruitment and Real World Evidence (RWE) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Clinical Trial Supply and Logistics for Pharmaceutical Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportClinitek Advantus Analyzer Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportClinker Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportClinkerr Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportClip Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportClip On Wheel Balance Weight Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportClip-On Ammeter Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportClip-on Wireless Microphone Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportClivia Miniata Market
Market size, share, segmentation and regional forecast.
$523M market · 2025 base year
View reportCLMV Specialised Container Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportClobetasone butyrate CAS 25122-57-0 Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportClock & Timer Development Kits Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.